Ozone therapy immunomodulatory effect in the selective immunoglobulin A deficiency.
DOI:
https://doi.org/10.7203/jo3t.1.1.2015.12161Parole chiave:
ozone thrapy, inmunology, selective IgA deficiency, immunological parameters, cytokines, subcutaneous Hebertrans
Abstract
The aim of this work is to study the ozone therapy effect in the selective immunoglobulin A deficiency. Taking into account that ozone is able to stimulate several biological systems, to modulate cytokines levels and to enhance immunoglobulin production, a phase II, controlled and randomized, clinical trial was performed. Forty patients were divided at random into 2 groups of 20 patients each: Ozone – received 42 sessions by rectal insufflations during three months, using scaling doses. Control – received subcutaneous Hebertrans during three months. Patients were evaluated at the beginning and one and six months later. The IgA improved, with significant difference (p=0.04) between both groups. The blood levels of IgG were increased significantly (p=0.03) in the group treated with ozone compared to the control group. Leukocyte activity improved significantly (p=0.04) one month later, achieving 97 % of normal values. The clinical evolution was satisfactory in 87 and 80 % of the children that received ozone and Hebertrans, respectively without side effects reported.
Downloads
Riferimenti bibliografici
Bradley AL, Trivikram D, James WV. Laboratory Diagnosis of Primary Immunodeficiencies. Clinic Rev Allerg Immunol. 2014;46:154-168.
Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Frontiers in immunology. 2014;5(162):1-32.
Abbas AK. Regional Immunity: Specialized immune response in epithelial and immune privileged tissues. In: Abbas AK, Lichtman A. Cellular and Molecular Immunology. 7 ed. NY: WB Saunders Co; 2011.
Abbas AK. Congenital and acquired immunodeficiencies: Specialized immune response in epithelial and immune privileged tissues. In: Abbas AK, Lichtman A. Cellular and Molecular Immunology. 7 ed. NY: WB Saunders Co; 2011.
Yel L. Selective IgA deficiency. J Clin Immunol. 2010;30(1):10-6.
Bezrodnik L, Giovanni D, Ginaca A. Evaluación clínica e inmunológica de 90 pacientes con deficiencia selectiva de inmunoglobulina A. Arch Argent Pediatr. 2008;10(5):375-381.
Singh K, Chang C, Gershwin ME. IgA deficiency and autoimmunity. Autoimmunity Reviews. 2014;13(2):163-177.
Fitzsimons MG, Walton K, Makar R, Dzik W, Kuter D, Vlahakes GJ. Redo aortic valve replacement in a patient with immunoglobulin A deficiency and hemophilia A. Ann Thorax Surg. 2013;96(1):311-313.
Domínguez O, Giner MT, Alsina L, Martín MA, Lozano J, Plaza AM. Fenotipos clínicos asociados a la deficiencia selectiva de IgA: revision de 330 casos y propuesta de un protocolo de seguimiento. An Pediatr. 2012;76(5):261-267.
Unknown-author. Transfer factor. Available from: http://www.factordetransferenciaipn.com.mx/queesft.htm. [Accessed 1th Mar 2009]
Inclan G, et al. Immunological and clinical response in patients with IgA deficiency after the treatment with transfer factor. Haematol immunol and Haemotherapy. 1994;10:80-81.
Bocci V. Biological and clinical effects of ozone. Has ozone therapy a future in medicine?. British Journal of Biomedical Science. 1999;56(4):270-279.
Menendez S, Gonzalez R, Ladea OE, Leon OS, Hernandez F, Díaz M. Ozonoterapia: Aspectos basicos y aplicaciones clínicas. La Habana, Cuba: Editorial CENIC; 2008.
Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear cells. Toxicology in Vitro. 2005;19:55-61.
Bocci V. Scientific and medical aspects of ozone Therapy. State of the art. Arch Med Res. 2006;37:425-435.
Travagli V, Zanardei I, Silvietti A, Bocci V. A physicochemical investigation on the effect of ozone on blood. Int J Biol Macromol. 2007;41:504-511.
Bocci V, Borrelli E, Corradeshi F, Valacchi G. Systemic effects after colorectal insufflations of oxygen-ozone in rabbits. Int J Med Biol Environ. 2000;28:109-113.
Ajamieh HH, Menendez S, Merino N, Martínez G, Re L, Leon OS. Ischemic and ozone oxidative preconditioning in the protection against hepatic ischemic-reperfusion injury. Ozone Sci Eng. 2003;25(3):241-50.
Calunga JL, Trujillo Y, Menendez S, Zamora Z, Alonso Y, Merino N, et al. Ozone oxidative postconditioning in acute renal failure. J Pharm Pharmacol. 2009;61:1-7.
Martinez G, Al-Dalain SM, Menendez S, Re L, Giuliani A, Candelario-Jalil E, et al. Therapeutic efficacy of ozone medical treatments in patients with diabetic foot. Eur J Pharmacol. 2005;523:151-161.
Hernandez F, Calunga JL, Turrent J, Menendez S, Montenegro A. Ozone therapy effects on blood biomarkers and lung fuction of asthma patients. Arch Med Res. 2005;36(5):549-554.
Ajamieh HH, Menendez S, Martinez-Sanchez G, Candelario-Jalil E, Re L, Giuliani A, et al. Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischaemia-reperfusion. Liver Int. 2004;24:55-62.
Viebahn R. The use of ozone in Medicine. 3rd English ed. Iffezheim, Germany: ODREI-Publishers; 1999.
Alonso I, et al. Formulario Nacional de Medicamentos. Segunda edicion. La Habana: Ed. Ciencias Medicas; 2011.
Hoffman R, Benz EJ, Shattil SS, et al. Hematology: Basic Principles and Practice. 4th ed. Orlando, Fl: Churchill Livingstone; 2005.
Ronald JH, Giclas PC. Diagnostic Immunology Laboratory Manual. New York, USA: Raven Press; 1991.
Suardíaz J, Cruz C, Colina A. Laboratorio Clinico. 1 ed. La Habana: Editorial Ciencias Medicas; 2004.
Weber-Mezell D, Kotanko P, Hauer AC, et al. Gender, age and seasonal effect on IgA deficiency: A study of 7293 Caucasians. Eur J Clin Invest. 2004;34(3):224-229.
Mendez IJ, Bellanti JA, Ovilla MR. Inmunodeficiencias primarias y alergia. Alerg Asma Inmunol Pediatr. 2008;17(1):14-34.
Urm SH, Yun HD, Fenta YA, Yoo KH, Abraham RS, Hagan J. Asthma and risk of selective IgA deficiency or common variable immunodeficiency: a population-based case-control study. Mayo Clin Proc. 2013;88(8):813-21.
Notarangelo L, Casanova JL, Fisher A, Puck J, Rosen F, Seger R, Geha G. Primary immunodeficiency diseases: Na update. J Allergy Clin Immun. 2004;114:677-687.
Barrios M. Clinical evolution of the patient default of IgA treated with Transference factor. Hemat Imm Transf Med. 2004;20(3):180-184.
Bocci V, Luzzi E, Corradeshi F, Paulesu L, Di-Stefano A. Studies on the biological effects of ozone. An attempt to define conditions for optimal induction of cytokines. Lymphokine and Cytokine Res. 1993;12:121-126.
Bocci V. Ozonization of blood for the therapy of viral diseases and immunodeficiencies. A hypothesis. Medical hypotesis. 1992;39:30-34.
Bocci V, Borrelli E, Zanardi I, Travagli V. Oxygen-ozone therapy is at a cross-road. Revista Española de Ozonoterapia. 2011;1(1):74-86.
Paulesu L, Luzzi E, Bocci V. Studies on the biological effects of ozone: 2. Induction of tumor necrosis factor (TNF ά) on human leucocytes. Lymphokines Cytokines Res. 1991;10:409-412.
Curse JM, Lewis RE. Atlas of Immunology. Second Edition. Florida: CRC Press; 2004.
Rhee SG, Bae YS, Lee SR, Kwon J. Hydrogen peroxide. A key messenger that modulates protein phosphorylation though cysteine oxidation. Sci STKE. 2000;2000(53):1. PubMed PMID: 11752613. doi: 10.1126/stke.2000.53.pe1.
Stites DP, Terr AI, Parslow TG. Inmunologia basica y clinica. Novena Edicion. Mexico: El Manual Moderno, S.A de C.V; 1998.
Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med. 2000;343:1703-1713.
Aderem A. Underbil DM. Mechanism of phagocytes in Macrophages. Ann Rev Immunol. 2009;170:553-623.
Guanche D, Zamora Z, Hernandez F, et al. Effect of ozone/oxygen mixture on systemic oxidative stress and organic damage. Toxicol Mech Methods. 2010;20(1):25-30.
Aubourg P. L'ozone medical: Production, posologie, modes d'applications cliniques. Bull Med Soc Med Paris. 1938;52:745-749.
Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharm. 2006;216:493-504.
Downloads
Pubblicato
Come citare
-
Abstract1894
-
PDF 859
-
HTML 2032
Fascicolo
Sezione
Licenza
Journal of Ozone Therapy applies the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY NC 4.0) license to works we publish.
Under this license, authors retain ownership of the copyright for their content, but allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. No permission is required from the authors or the publishers.
You may not use the material for commercial purposes.
Appropriate attribution can be provided by simply citing the original article, provide a link to the license, and indicate if changes were made.
You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Articoli simili
Puoi leggere altri articoli dello stesso autore/i
Fai una proposta
Lingua
Informazioni
Keywords
